Benedikt A Aulinger1, Torsten P Vahl1, Hilary E Wilson-Pérez1, Ron L Prigeon1, David A D'Alessio1. 1. Division of Endocrinology, Diabetes, and Metabolism (B.A.A., T.P.V., H.E.W.-P., D.A.D.), Department of Medicine, University of Cincinnati, Cincinnati, Ohio 45267; University of Maryland School of Medicine (R.L.P.), and Baltimore Veterans Affairs Medical Center, Baltimore, Maryland 21201; and Cincinnati Veterans Affairs Medical Center (D.A.D.), Cincinnati, Ohio 45220.
Abstract
CONTEXT: Glucagon-like peptide-1 (GLP-1) is an insulinotropic factor made in the gastrointestinal tract that is essential for normal glucose tolerance. Infusion of GLP-1 increases insulin secretion in both diabetic and nondiabetic humans. However, the degree to which people vary in their β-cell sensitivity to GLP-1 and the factors contributing to this variability have not been reported. OBJECTIVE: The objective was to measure the sensitivity of insulin secretion to GLP-1 in cohorts of lean and obese subjects across a broad range of insulin sensitivity. METHODS: Insulin secretion was measured during clamped hyperglycemia (7.2 mmol/L) and graded GLP-1 infusion in young, healthy subjects, and GLP-1 sensitivity was computed from the insulin secretion rate (ISR) during progressive increases in plasma GLP-1. RESULTS: All subjects had fasting glucose values <5.2 mm. The obese subjects were insulin resistant compared to the lean group (homeostasis model of assessment 2 for insulin resistance: obese, 2.6 ± 0.5; lean, 0.8 ± 0.1; P < .001). ISR increased linearly in both cohorts with escalating doses of GLP-1, but the slope of ISR in response to GLP-1 was greater in the obese than in the lean subjects (obese, 0.17 ± 0.03 nmol/min/pm; lean, 0.05 ± 0.01 nmol/min/pm; P < .001). There was a significant association of β-cell GLP-1 sensitivity and insulin resistance (r = 0.83; P < .001), and after correction for homeostasis model of assessment 2 for insulin resistance, the slopes of ISR vs GLP-1 concentration did not differ in the two cohorts (obese, 0.08 ± 0.01; lean, 0.08 ± 0.01; P = .98). However, within the entire study group, β-cell GLP-1 sensitivity corrected for insulin resistance varied nearly 10-fold. CONCLUSIONS: Insulin secretion in response to GLP-1 is proportional to insulin resistance in healthy subjects. However, there is considerable variability in the sensitivity of the β-cell to GLP-1 that is independent of insulin sensitivity.
CONTEXT: Glucagon-like peptide-1 (GLP-1) is an insulinotropic factor made in the gastrointestinal tract that is essential for normal glucose tolerance. Infusion of GLP-1increases insulin secretion in both diabetic and nondiabetic humans. However, the degree to which people vary in their β-cell sensitivity to GLP-1 and the factors contributing to this variability have not been reported. OBJECTIVE: The objective was to measure the sensitivity of insulin secretion to GLP-1 in cohorts of lean and obese subjects across a broad range of insulin sensitivity. METHODS:Insulin secretion was measured during clamped hyperglycemia (7.2 mmol/L) and graded GLP-1 infusion in young, healthy subjects, and GLP-1 sensitivity was computed from the insulin secretion rate (ISR) during progressive increases in plasma GLP-1. RESULTS: All subjects had fasting glucose values <5.2 mm. The obese subjects were insulin resistant compared to the lean group (homeostasis model of assessment 2 for insulin resistance: obese, 2.6 ± 0.5; lean, 0.8 ± 0.1; P < .001). ISR increased linearly in both cohorts with escalating doses of GLP-1, but the slope of ISR in response to GLP-1 was greater in the obese than in the lean subjects (obese, 0.17 ± 0.03 nmol/min/pm; lean, 0.05 ± 0.01 nmol/min/pm; P < .001). There was a significant association of β-cell GLP-1 sensitivity and insulin resistance (r = 0.83; P < .001), and after correction for homeostasis model of assessment 2 for insulin resistance, the slopes of ISR vs GLP-1 concentration did not differ in the two cohorts (obese, 0.08 ± 0.01; lean, 0.08 ± 0.01; P = .98). However, within the entire study group, β-cell GLP-1 sensitivity corrected for insulin resistance varied nearly 10-fold. CONCLUSIONS:Insulin secretion in response to GLP-1 is proportional to insulin resistance in healthy subjects. However, there is considerable variability in the sensitivity of the β-cell to GLP-1 that is independent of insulin sensitivity.
Authors: Torsten P Vahl; Breay W Paty; Bradley D Fuller; Ronald L Prigeon; David A D'Alessio Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: Filip K Knop; K Aaboe; T Vilsbøll; A Vølund; J J Holst; T Krarup; S Madsbad Journal: Diabetes Obes Metab Date: 2012-01-17 Impact factor: 6.577
Authors: K S Polonsky; B D Given; L Hirsch; E T Shapiro; H Tillil; C Beebe; J A Galloway; B H Frank; T Karrison; E Van Cauter Journal: J Clin Invest Date: 1988-02 Impact factor: 14.808
Authors: Sarah M Gray; Yurong Xin; Elizabeth C Ross; Bryanna M Chazotte; Megan E Capozzi; Kimberley El; Berit Svendsen; Peter Ravn; Kyle W Sloop; Jenny Tong; Jesper Gromada; Jonathan E Campbell; David A D'Alessio Journal: J Biol Chem Date: 2020-06-18 Impact factor: 5.157
Authors: Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary Journal: Physiol Rev Date: 2017-01 Impact factor: 37.312
Authors: Sarah M Gray; Andrew L Hoselton; Radha Krishna; Cris A Slentz; David A D'Alessio Journal: J Clin Endocrinol Metab Date: 2022-08-18 Impact factor: 6.134
Authors: Benedikt A Aulinger; Torsten P Vahl; Ron L Prigeon; David A D'Alessio; Deborah A Elder Journal: Am J Physiol Endocrinol Metab Date: 2016-03-15 Impact factor: 4.310
Authors: Benedikt A Aulinger; Marta Perabo; Randy J Seeley; Klaus G Parhofer; David A D'Alessio Journal: Am J Physiol Endocrinol Metab Date: 2019-11-19 Impact factor: 4.310
Authors: Alexandra G Yunker; Shan Luo; Sabrina Jones; Hilary M Dorton; Jasmin M Alves; Brendan Angelo; Alexis DeFendis; Trevor A Pickering; John R Monterosso; Kathleen A Page Journal: J Clin Endocrinol Metab Date: 2021-03-08 Impact factor: 5.958